Pharmacological modulation of Alzheimer's β-amyloid precursor protein levels in the CSF of rats with forebrain cholinergic system lesions

Molecular Brain Research

Volumn 46, Issue 1-2, 1997, Pages 161-168

  Haroutunian, V ^a   Greig, N ^b   Pei, X F ^b   Utsuki, T ^b   Gluck, R ^a   Acevedo, L D ^b   Davis, K L ^a   Wallace, W C ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b Laboratory of Membrane Biochemistry and Biophysics   (United States)

Author keywords

Acetylcholine; Acetylcholinesterase; Acetylcholinesterase inhibitor; Alzheimer's disease; Amyloid protein; Amyloid protein, precursor; Basal nucleus of Meynert; Butyrylcholinesterase; Cerebral cortex; Cerebrospinal fluid; DFP; In vivo; Phenserine; Rat; Receptor, muscarinic

Indexed keywords

AMYLOID BETA PROTEIN; CHOLINESTERASE INHIBITOR; DYFLOS; PROTEIN PRECURSOR; SCOPOLAMINE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CEREBROSPINAL FLUID; CHOLINERGIC NERVE CELL; CHOLINERGIC SYSTEM; CONTROLLED STUDY; DEGENERATION; FOREBRAIN; MALE; NONHUMAN; OLIVARY NUCLEUS; PRIORITY JOURNAL; RAT;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; CHOLINESTERASE INHIBITORS; ISOFLUROPHATE; MALE; MUSCARINIC ANTAGONISTS; PHYSOSTIGMINE; PROSENCEPHALON; RATS; RATS, SPRAGUE-DAWLEY; SCOPOLAMINE;

EID: 0030986003     PISSN: 0169328X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-328X(96)00297-5     Document Type: Article

References (59)

1. Anderson, J., Wallace, W., Snyder, S., Haroutunian, V., Roberts, J.L. and Lieberburg, I., Cellular forms of the rat and human betaamyloid precursor protein (BAPP), Brain Res., 478 (1989) 391-398.
2. Anderson, J.P., Chen, Y., Kim, K.S. and Robakis, N.K., An alternative secretase cleavage produces soluble Alzheimer amyloid precursor protein containing a potentially amyloidogenic sequence, J. Neurochem., 59 (1992) 2328-2331.
3. Beeson, J., Shelton, E., Chan, H. and Gage, F., Age and damage induced changes in amyloid protein precursor immunohistochemistry in the rat brain, Comp. Neurol., 342 (1994) 69-77.
4. Beller, S.A., Overall, J.E., Rhoades, H.M. and Swann, A.C., Long-term outpatient treatment of senile dementia with oral physostigmine, J. Clin. Psychiatry, 49 (1988) 400-404.
5. Bierer, L., Haroutunian, V., Gabriel, S., Knott, P., Carlin, L., Dushyant, P., Perl, D., Schmeidler, J., Kanof, P. and Davis, K., Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits, J. Neurochem., 64 (1995) 749-760.
6. Blozovski, D. and Hennocq, N., Effects of antimuscarinic cholinergic drugs injected systemically or into the hippocampo-entorhinal area upon passive avoidance learning in young rats, Psychopharmacology, 76 (1982) 351-358.
7. Bradford, M.M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding, Anal. Biochem., 72 (1976) 248-254.
8. Brzostowska, M., He, X.S., Greig, N.H., Rapaport, S. and Brossi, A., Selective inhibition of acetyl- and butyrylcholinesterases by phenylcarbamates of (-)-eseroline, (-)-(N1)-noreseroline and physovenol, Med. Chem. Res., 2 (1992) 238-246.
9. Buxbaum, J., Oishi, M., Chen, H., Pinkas-Kramarski, R., Jaffe, E., Gandy, S. and Greengard, P., Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer B/A4 amyloid protein precursor, Proc. Natl. Acad. Sci. USA, 89 (1992) 10075-10078.
10. Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A.Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I. and Selkoe, D.J., Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production, Nature (London), 360 (1992) 672-674.
11. Consolo, S., Ladinsky, H., Peri, G. and Garattini, S., Effect of central stimulants and depressants on mouse brain acetylcholine and choline levels, Eur. J. Pharmacol., 18 (1972) 251-255.
12. Davis, K., Yang, R., Davidson, M., Mohs, R., Ryan, T., Schmeidler, J., Knott, P., Thal, L. and Gamzu, E., Tacrine Collaborative Study Group, Alzheimer's disease: tacrine and tacrine metabolite concentrations in plasma and cognitive change, Drug Dev. Res., 34 (1995) 55-65.
13. Davis, K.L. and Haroutunian, V., Strategies for the treatment of multi-neurotransmitter deficits in Alzheimer's disease. In Z.S. Khachaturian and J.P. Blass (Eds.), Alzheimer's Disease: New Treatment Strategies, Marcel Dekker, New York, NY, 1992, pp. 23-36.
14. Davis, K.L., Thal, L.T., Gamzu, E.R., Davis, C.S., Woolfson, R.F., Gracon, S.I., Drachman, D.A., Schneider, L.S., Whitehouse, P.J., Hoover, T.N., Morris, J.C., Kawas, C.H., Knopman, D.S., Earl, N.L., Kumar, W. and Doody, R.S., A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease, New Engl. J. Med., 327 (1992) 1253-1259.
15. Dekker, A.J., Connor, D.J. and Thal, L.J., The role of cholinergic projections from the nucleus basalis in memory, Neurosci. Biobehav. Rev. 15 (1991) 299-317.
16. DeKosky, S.T., Harbaugh, R.E., Schmitt, F.A., Bakay, R.A., Chui, H.C., Knopman, D.S., Reeder, T.M., Shetter, A.G., Senter, H.J. and Markesbery, W.R., Cortical biopsy in Alzheimer's disease: diagnostic accuracy and neurochemical, neuropathological, and cognitive correlations. Intraventricular Bethanecol Study Group, Ann. Neurol., 32 (1992) 625-632.
17. Ellman, G.L., Courtney, D.K., Valentino, A.J. and Featherstone, R.M., A new and rapid colorimetric determination of acetylcholin-esterase activity, Biochem. Pharmacol., 7 (1961) 88-95.
18. Farber, S., Nitsch, R., Schulz, J. and Wurtman, R., Regulated secretion of β-amyloid precursor protein in rat brain, J. Neurosci., 15 (1995) 7442-7451.
19. Giacobini, E., Therapy for Alzheimer's disease. Symptomatic or neuroprotective?, Mol. Neurobiol., 9 (1994) 115-118.
20. Glisson, S., Karczmar, A. and Barnes, L., Effects of dIIsopropyl phosphorofluoridate on acetylcholine, cholinesterase and catecholamines of several parts of rabbit brain, Neuropharmacology, 13 (1974) 623-631.
21. Goate, A., Chartier-Harlin, M., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., Mant, R., Newton, P., Rook, K., Roques, P., Talbot, C., Pericak-Vance, M., Roses, A., Williamson, R., Rossor, M., Owen, M. and Hardy, J., Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease, Nature (London), 349 (1991) 704-706.
22. Granon, S., Poucet, B., Thinus-Blanc, C., Changeux, J. and Vidal, C., Nicotinic and muscarinic receptors in the rat prefrontal cortex: differential roles in working memory, response selection and effortful processing, Psychopharmacology, 119 (1995) 139-144.
23. Gray, J., Enz, A. and Spiegel, R., Muscarinic agonists for senile dementia: past experience and future trends, TiPS, (1989) 85-88.
24. Greig, N.H., Pei, X.-F., Soncrant, T.T., Ingram, D.K. and Brossi, A., Phenserine and ring C hetero-analogues: drug candidates for the treatment of Alzheimer's disease, Med. Res. Rev., 15 (1995) 3-31.
25. Grob, D. and Harvey, J.C., Effects in man of the anticholinesterase compound sarin (isopropyl methyl phosphonofluoridate), J. Clin. Invest., 37 (1958) 350-368.
26. Hakansson, L., Mechanism of action of cholinesterase inhibitors in Alzheimer's disease, Acta Neurol. Scand. Suppl., 149 (1993) 7-9.
27. Haroutunian, V., Kanof, P. and Davis, K.L., Pharmacological alleviation of cholinergic lesions induced memory deficits in rats, Life Sci., 37 (1985) 945-952.
28. Haroutunian, V., Mantin, R., Campbell, G.A., Tsuboyama, D.K. and Davis, K.L., Cysteamine-induced depletion of central somatostatin-like immunoactivity: effects on behavior, learning, memory and brain neurochemistry, Brain Res., 403 (1987) 234-242.
29. Haroutunian, V., Wallace, W., Santucci, A.C. and Davis, K.L., Animal models of neurotransmitter interactions in Alzheimer's disease. In J.L. McGaugh (Ed.), Proceedings of the Fifth Conference on the Neurobiology of Learning and Memory, Birkhauser, New York, NY, 1995, pp. 127-151.
30. Hughes, R., A review of atropinic drug effects on exploratory choice behavior in laboratory rodents, Behav. Neural Biol., 34 (1982) 5-41.
31. Iijima, S., Greig, N.H., Garofalo, P., Spangler, E.L., Heller, B., Brossi, A. and Ingram, D.K., The long-acting cholinesterase inhibitor heptyl-physostigmine attenuates the scopolamine-induced learning impairment of rats in a 14-unit T-maze, Neurosci. Lett., 144 (1992) 79-83.
32. Iijima, S., Greig, N.H., Garofalo, P., Spangler, E.L., Heller, B., Brossi, A. and Ingram, D.K., Phenserine: a physostigmine derivative that is a long-acting inhibitor of acetylcholinesterase and demonstrates a wide dose-range for attenuating a scopolamine-induced learning impairment of rats in a 14-unit T-maze, Psychopharmacology, 112 (1993) 415-420.
33. Ikari, H., Spangler, E.L., Greig, N.H., Pei, X.-F., Brossi, A., Speer, D., Patel, N. and Ingram, D.K., Performance of aged rats in a 14-unit T-maze is improved following chronic treatment with phenserine, a novel long-acting anticholinesterase, NeuroReport, 6 (1995) 481-484.
34. Johnson, C.D. and Russell, R.L., A rapid, simple radiometric assay for acetylcholinesterase, suitable for multiple determinations, Anal. Biochem., 64 (1975) 229-232.
35. Lahiri, D., Reversibility of the effect of tacrine on the secretion of the β-amyloid precursor protein in cultured cells, Neurosci. Lett., 181 (1994) 149-142.
36. Lahiri, D., Lewis, S. and Farlow, M., Tacrine alters the secretion of the beta-amyloid precursor protein in cell lines, J. Neurosci. Res., 37 (1994) 777-787.
37. Lahiri, D.K., Nall, C. and Farlow, M.R., The cholinergic agonist carbachol reduces intracellular beta-amyloid precursor protein in PC 12 and C6 cells, Biochem. Int., 28 (1992) 853-860.
38. Marrs, T., Organophosphate poisoning, Pharmacol. Ther., 58 (1993) 51-66.
39. Masters, C.L., Simms, G., Weinman, N.A., Multraup, G., McDonald, B.L. and Beyreuther, K., Amyloid plaque core protein in Alzheimer's disease and Downs syndrome, PNAS, 82 (1985) 4245-4249.
40. Mohs, R.C., Davis, B.M., Johns, C.A., Mathe, A.A., Greenwald, B.S., Horvath, T.B. and Davis, K.L., Oral physostigmine treatment of patients with AD, Am. J. Psychiatry, 142 (1985) 28-33.
41. Molchan, S.E., Martinez, R.A., Hill, J.L., Weingartner, H.J., Thompson, K., Vitiello, B. and Sunderland, T., Increased cognitve sensitivity to scopolamine with age and a perspective on the scopolamine model, Brain Res. Rev., 17 (1992) 215-226.
42. Murray, C.L. and Fibiger, H.C., Learning and memory deficits after lesions of the nucleus basalis magnocellularis: reversal by physostigmine, Neuroscience, 19 (1985) 1025-1032.
43. Nitsch, R.M., Slack, B.E., Wurtman, R.J. and Growdon, J.H., Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors, Science, 258 (1992) 304-307.
44. Olton, D.S., Dementia: animal models of the cognitive impairments following damage to the basal forebrain cholinergic system, Brain Res. Bull., 25 (1990) 499-502.
45. Paxinos, G. and Watson, C., The Rat Brain in Stereotaxic Coordinates, Academic Press, New York, NY, 1986.
46. Perry, E.K., Tomlinson, B.E., Blessed, G., Bergmann, K., Gibson, P.H. and Perry, R.H., Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia, Br. Med. J., 2 (1978) 1457-1459.
47. Ridley, R.M., Murray, T.K., Johnson, J.A. and Baker, H.F., Learning impairment following lesions of the basal nucleus of Meynert in the marmoset: modification by cholinergic drugs, Brain Res., 376 (1986) 108-116.
48. Santucci, A.C., Haroutunian, V., Tsuboyama, G.K., Kanof, P.D. and Davis, K.L., Therapeutics of Alzheimer's disease for clinical and pre-clinical issues. In K. Iqbal, H.M. Wisniewski and B. Winblad (Eds.), Progress in Clinical and Biological Research, Alan R. Liss, New York, NY, 1989, pp. 1111-1120.
49. Selkoe, D.J., Normal and abnormal biology of the β-amyloid precursor protein, Annu. Rev. Neurosci., 17 (1994) 489-517.
50. Selkoe, D.J., Abraham, C.R., Podlisny, M.B. and Duffy, L.K., Isolation of low-molecular-weight proteins from amyloid plaque fibers in Alzheimer's disease, J. Neurochem., 146 (1986) 1820-1834.
51. Storey, P.L., Harrell, L.E., Duke, L.W., Callaway, R. and Marson, D.C., Does chronic oral physostigmine alter the course of Alzheimer's disease? In B. Corain, K. Iqbal, M. Nicolini, B. Winblad, H. Wisnieski and P. Zatta (Eds.), Alzheimer's Disease: Advances in Clinical and Brain Research, John Wiley & Sons, New York, NY, 1993, pp. 563-568.
52. Thal, L.J., Masur, D.M., Blau, A.D., Fuld, P.A. and Klaiber, M.R., Chronic oral physostigmine without lecethin improves memory in Alzheimer's disease, J. Am. Geriatr. Soc., 37 (1989) 42-48.
53. Vige, X. and Briley, M., Muscarinic receptor plasticity in rats lesioned in the nucleus basalis of Meynert, Neuropharmacology, 28 (1989) 727-732.
54. Wallace, W., Ahlers, S.T., Gotlib, J., Bragin, V., Sugar, J., Gluck, R., Shea, P.A., Davis, K.L. and Haroutunian, V., Amyloid precursor protein in the cerebral cortex is rapidly and persistently induced by loss of subcortical innervation, Proc. Natl. Acad. Sci USA, 90 (1993) 8712-8716.
55. Wallace, W., Ahlers, S.T., Gotlib, J., Bragin, V., Sugar, J., Gluck, R., Shea, P.A., Davis, K.L. and Haroutunian, V., Amyloid precursor protein in the cerebral cortex is rapidly and persistently induced by loss of subcortical innervation, Proc. Natl. Acad. Sci. USA, 90 (1993) 8712-8716.
56. Wallace, W., Lieberburg, I., Schenk, D., Vigo-Pelfrey, C., Davis, K. and Haroutunian, V., Chronic elevation of secreted amyloid precursor protein in subcortically lesioned rats, and its exacerbation in aged rats, J. Neurosci., 15 (1995) 4896-4905.
57. Wallace, W.C., Bragin, V., Robakis, N.K., Sambamurti, K., Vanderputten, D., Merril, C.R., Davis, K.L., Santucci, A.C. and Haroutunian, V., Increased biosynthesis of Alzheimer amyloid precursor protein in the cerebral cortex of rats with lesions of the nucleus basalis of Meynert, Mol. Brain Res., 10 (1991) 173-178.
58. Weiner, N., Atropine, scopolamine, and related antimuscarinic drugs. In A. Goodman Gilman, L.S. Goodman, T.W. Rall and F. Murad (Eds.), The Pharmacological Basis of Therapeutics, Macmillan, New York, NY, 1985, pp. 130-144.
59. Whitehouse, P.J., Cholinergic therapy in dementia, Acta Neurol. Scand. Suppl., 149 (1993) 42-45.